Patents by Inventor Rajiv Indravadan Modi
Rajiv Indravadan Modi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10882819Abstract: The present invention relates to novel intermediate(s), which are useful for the preparation of Rivastigmine compound of formula (I) and its pharmaceutically acceptable salts. The present invention further relates to the processes for the preparation of such novel intermediate(s) and preparation of Rivastigmine using such novel intermediate(s).Type: GrantFiled: September 25, 2019Date of Patent: January 5, 2021Assignee: Cadila Corporate CampusInventors: Jhillu Singh Yadav, Gyanchander Eppa, Pranav Rameshbhai Vachharajani, Nutan Bharatbhai Vekariya, Chetan Umeshbhai Bhavsar, Rajiv Indravadan Modi, Bakulesh Mafatlal Khamar
-
Publication number: 20200095195Abstract: The present invention relates to novel intermediate(s), which are useful for the preparation of Rivastigmine compound of formula (I) and its pharmaceutically acceptable salts. The present invention further relates to the processes for the preparation of such novel intermediate(s) and preparation of Rivastigmine using such novel intermediate(s).Type: ApplicationFiled: September 25, 2019Publication date: March 26, 2020Applicant: Cadila Pharmaceuticals, Ltd.Inventors: Jhillu Singh Yadav, Gyanchander Eppa, Pranav Rameshbhai Vachharajani, Nutan Bharatbhai Vekariya, Chetan Umeshbhai Bhavsar, Rajiv Indravadan Modi, Bakulesh Mafatlal Khamar
-
Publication number: 20180042850Abstract: The present invention relates to a lyophilized composition comprising killed cancer cells with substantially retained immunogenicity and morphology, an intracellular cryopreservative such as trehalose and an extracellular cryopreservative such as polyvinylpyrrolidone. The present invention also relates to a process for the preparation of said lyophilized composition. The lyophilized composition of the present invention can be used for cancer immunotherapy.Type: ApplicationFiled: October 2, 2017Publication date: February 15, 2018Applicant: Cadila Pharmaceuticals Ltd.Inventors: Bakulesh Mafatlal Khamar, Satinder Singh, Nirav Manojkumar Desai, Rajiv Indravadan Modi
-
Patent number: 9795659Abstract: This invention discloses the process for lyophilization of the treated cells which comprises the use of a solution containing Trehalose along with amphipathic polymer Polyvinylpyrrolidone. Further the invention discloses the process treating cancer cells, freezing, lyophilizing and reconstituting. Immunomodulator treated dead, but intact cancerous cells were recovered, which can subsequently be used for cancer immunotherapy.Type: GrantFiled: February 17, 2011Date of Patent: October 24, 2017Assignee: Cadila Pharmaceuticals, Ltd.Inventors: Bakulesh Mafatlal Khamar, Satinder Singh, Nirav Manojkumar Desai, Rajiv Indravadan Modi
-
Patent number: 9789187Abstract: The present invention relates to a stable solid oral pharmaceutical multi-component composition comprising combination of blood pressure lowering drugs with lipid lowering agent/s and optionally a platelet aggregation inhibitor in a single dosage form. The blood pressure lowering agents are selected from ?-adrenergic receptor blocking agent, ACE inhibitor and diuretic. The lipid lowering agent is selected from HMG Co-enzyme-A reductase inhibitor. The pharmaceutical composition made as per present invention a) overcomes any drug-drug interactions, b) exhibits pharmacokinetic and pharmacodynamic profile of individual therapeutic agent, c) has minimal side effects. The invention provides multi-component composition (MCC) to increase adherences to therapy. The MCC as per present invention provides compositions that maintain activity of all active ingredients without significant increase in adverse event profile. The present invention further relates to a method of preparing the said pharmaceutical composition.Type: GrantFiled: February 8, 2010Date of Patent: October 17, 2017Assignee: Cadila Pharmaceuticals LimitedInventors: Bakulesh Mafatlal Khamar, Kumud Kumar Padhee, Nilamkumari Somalal Patel, Sunil Chowdary Koduri, Amit Mukharya, Indravadan Ambalal Modi, Rajiv Indravadan Modi
-
Patent number: 9714275Abstract: Cancer cells when treated with cisplatin, paclitaxel, gemcitabine, Mycobacterium w or combination there of shows altered protein profile. Thus altered protein profile has at least one protein commonly expressed or over expressed. The commonly expressed or over expressed protein induces immune response specific to cancer cells (homologue and hetrologus) of tissue/organ of origin. The immune response generated by administration of commonly expressed or over expressed antigen not reactive to normal cells and cancer cells or different tissue/organ of origin.Type: GrantFiled: July 4, 2012Date of Patent: July 25, 2017Assignee: Cadila Pharmaceuticals Ltd.Inventors: Indravadan Ambalal Modi, Rajiv Indravadan Modi, Bakulesh Mafatlal Khamar, Chandreshwar Prasad Shukla, Vipul Sitaram Thakkar, Nirav Manojkumar Desai
-
Patent number: 9708258Abstract: The present invention relates to novel stable indole-3-carbinol derivatives of Formula-I and its pharmaceutical composition and biological activity. The present invention includes compositions and methods for the treatment and prevention of conditions associated with Inflammation.Type: GrantFiled: July 11, 2014Date of Patent: July 18, 2017Assignee: Cadila Pharmaceuticals, Ltd.Inventors: Rajiv Indravadan Modi, Chandan Hardhan Singh, Niravkumar Sureshbhai Sagar, Sunilkumar Ramsuratbhai Tivari, Bipin Dhanajibhai Gadhiya
-
Patent number: 9474727Abstract: The present invention relates to stable liquid pharmaceutical compositions of curcumin or its pharmaceutically acceptable salts or its derivatives with higher curcumin concentration and improved bioavailability without the use of buffer and/or molecular aggregation inhibitor(s). In accordance with present invention the curcumin is in the solubilized form to make a stable liquid pharmaceutical composition.Type: GrantFiled: September 12, 2011Date of Patent: October 25, 2016Assignee: Cadila Pharmaceuticals LimitedInventors: Bakulesh Mafatlal Khamar, Ashish Premkumar Gogia, Chirag Chandrakant Goda, Dinesh Balkunje Shenoy, Rajneesh Ramesh Shrivastava, Vandana Bharat Patravale, Indravadan Ambalal Modi, Ritu Nitin Laddha, Imran Ahmad Khan, Rajiv Indravadan Modi
-
Patent number: 9029567Abstract: The present invention relates to novel hypoglycemic compounds of formula (1) and pharmaceutically acceptable salts thereof. The invention relates to novel amino acid derivatives of the formula (1), wherein, A is amino acid B is peptide bond R-NH- wherein R is defined in the specification.Type: GrantFiled: April 1, 2011Date of Patent: May 12, 2015Assignee: Cadila Pharmaceuticals LimitedInventors: Bakulesh Mafatlal Khamar, Chandan Singh, Rajiv Indravadan Modi
-
Publication number: 20140045771Abstract: The present invention is directed to novel compounds of formula I and pharmaceutically acceptable salts, enantiomers thereof having inhibiting properties of dipeptidyl peptidase IV enzyme (DP-IV inhibitors). The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds along with its composition in the prevention or treatment of diseases associated with DP-IV enzyme.Type: ApplicationFiled: October 21, 2013Publication date: February 13, 2014Applicant: Cadila Corporated CampusInventors: Bakulesh Mafatlal Khamar, Singh Chandan, Rajiv Indravadan Modi
-
Patent number: 8647643Abstract: The invention provides novel adjuvants and pharmaceutical composition comprising of an adjuvant alone. The invention also provides novel vaccine compositions comprising of an antigen and a novel adjuvant. The novel adjuvant as per present invention is farnesoid-X-receptor (FXR) antagonist. The invention also relates to an adjuvant for variety of antigens. The adjuvant improves antibody production specific to incorporated antigen. The adjuvant also induces cell mediated immune response.Type: GrantFiled: September 26, 2009Date of Patent: February 11, 2014Assignee: Cadila Pharmaceuticals, LtdInventors: Bakulesh Mafatlal Khamar, Indravadan Ambalal Modi, Rajiv Indravadan Modi
-
Patent number: 8563517Abstract: The present invention is directed to novel compounds of formula I and pharmaceutically acceptable salts, enantiomers thereof having inhibiting properties of dipeptidyl peptidase IV enzyme (DP-IV inhibitors). The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds along with its composition in the prevention or treatment of diseases associated with DP-IV enzyme. wherein, A is defined as R3-R4 wherein R3 and R4 are together or independently defined as peptides having amino acids ranging from 1 to 10, B is chemical bond between peptide and substituted amine, R1, and R2 are as defined in specification.Type: GrantFiled: September 11, 2009Date of Patent: October 22, 2013Assignee: Cadila Pharmaceuticals LimitedInventors: Bakulesh Mafatlal Khamar, Singh Chandan, Rajiv Indravadan Modi
-
Publication number: 20130225689Abstract: The present invention relates to stable liquid pharmaceutical compositions of curcumin or its pharmaceutically acceptable salts or its derivatives with higher curcumin concentration and improved bioavailability without the use of buffer and/or molecular aggregation inhibitor(s). In accordance with present invention the curcumin is in the solubilized form to make a stable liquid pharmaceutical composition.Type: ApplicationFiled: September 12, 2011Publication date: August 29, 2013Applicant: CADILA PHARMACEUTICALS LIMITEDInventor: Rajiv Indravadan Modi
-
Publication number: 20130150578Abstract: The present invention relates to novel hypoglycemic compounds of formula (1) and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: April 1, 2011Publication date: June 13, 2013Applicant: CADILA PHARMACEUTICALS LIMITEDInventors: Bakulesh Mafatlal Khamar, Chandan Singh, Rajiv Indravadan Modi
-
Publication number: 20120308605Abstract: This invention discloses the process for lyophilisation of the treated cells which comprises the use of a solution containing Trehalose along with amphipathic polymer Polyvinylpyrrolidone. Further the invention discloses the process treating cancer cells, freezing, lyophilizing and reconstituting. Immunomodulator treated dead, but intact cancerous cells were recovered, which can subsequently be used for cancer immunotherapy.Type: ApplicationFiled: February 17, 2011Publication date: December 6, 2012Applicant: Cadila Pharmaceuticals Ltd.Inventors: Bakulesh Mafatlal Khamar, Satinder Singh, Nirav Manojkumar Desai, Rajiv Indravadan Modi
-
Patent number: 8277778Abstract: The invention relates to a novel adjuvant Mycobacterium w and or its constituents and adjuvant containing composition, which contains antigen(s) with pharmaceutical acceptable carrier and its uses. Mycobacterium w and or its constituents when administered with antigen(s) to mammal results in enhanced immunogenicity of antigen. The enhanced immunogenicity manifests as humoral responses as well as cell mediated immunity. The adjuvant effect is seen with variety of antigens in various mammals irrespective of their immune status at the time of administration of Mycobacterium w and antigen containing composition. e.g. immune naïve or preimmunized status.Type: GrantFiled: September 23, 2011Date of Patent: October 2, 2012Assignee: Cadila Pharmaceuticals Ltd.Inventors: Bakulesh Mafatlal Khamar, Rajiv Indravadan Modi, Indravadan Ambalal Modi, Prasanta Kumar Ghosh, Nirav Desai
-
Patent number: 8153102Abstract: The invention relates to process for the preparation of formulations comprising a microorganism Mycobacterium w for the management of bronchial Asthma (obstructive lung disease).Type: GrantFiled: March 11, 2003Date of Patent: April 10, 2012Assignee: Cadila Pharmaceuticals Ltd.Inventors: Rajiv Indravadan Modi, Bakulesh Mafatlal Khamar
-
Publication number: 20120027849Abstract: The present invention relates to a stable solid oral pharmaceutical multi-component composition comprising combination of blood pressure lowering drugs with lipid lowering agent/s and optionally a platelet aggregation inhibitor in a single dosage form. The blood pressure lowering agents are selected from ?-adrenergic receptor blocking agent, ACE inhibitor and diuretic. The lipid lowering agent is selected from HMG Co-enzyme-A reductase inhibitor. The pharmaceutical composition made as per present invention a) overcomes any drug-drug interactions, b) exhibits pharmacokinetic and pharmacodynamic profile of individual therapeutic agent, c) has minimal side effects. The invention provides multi-component composition (MCC) to increase adherences to therapy. The MCC as per present invention provides compositions that maintain activity of all active ingredients without significant increase in adverse event profile. The present invention further relates to a method of preparing the said pharmaceutical composition.Type: ApplicationFiled: February 8, 2010Publication date: February 2, 2012Applicant: CADILA PHARMACEUTICALS LIMITEDInventors: Bakulesh Mafatlal Khamar, Kumud Kumar Padhee, Nilamkumari Somalal Patel, Sunil Chowdary Koduri, Amit Mukharya, Indravadan Ambalal Modi, Rajiv Indravadan Modi
-
Publication number: 20120014985Abstract: The invention relates to a novel adjuvant Mycobacterium w and or its constituents and adjuvant containing composition, which contains antigen (s) with pharmaceutical acceptable carrier and its uses. Mycobacterium w and or its constituents when administered with antigen (s) to mammal results in enhanced immunogenicity of antigen. The enhanced immunogenicity manifests as humoral responses as well as cell mediated immunity. The adjuvant effect is seen with variety of antigens in various mammals irrespective of their immune status at the time of administration of Mycobacterium w and antigen containing composition. e.g. immune naïve or preimmunised status.Type: ApplicationFiled: September 23, 2011Publication date: January 19, 2012Applicant: CADILA PHARMACEUTICALS LTD.Inventors: BAKULESH MAFATLAL KHAMAR, Rajiv Indravadan Modi, Indravadan Ambalal Modi, Prasanta Kumar Ghosh, Nirav Desai
-
Patent number: 8048434Abstract: The invention relates to a novel adjuvant Mycobacterium w and or its constituents and adjuvant containing composition, which contains antigen (s) with pharmaceutical acceptable carrier and its uses. Mycobacterium w and or its constituents when administered with antigen (s) to mammal results in enhanced immunogenicity of antigen. The enhanced immunogenicity manifests as humoral responses as well as cell mediated immunity. The adjuvant effect is seen with variety of antigens in various mammals irrespective of their immune status at the time of administration of Mycobacterium w and antigen containing composition. e.g. immune naïve or preimmunized status.Type: GrantFiled: April 21, 2006Date of Patent: November 1, 2011Assignee: Cadila Pharmaceuticals, Ltd.Inventors: Bakulesh Mafatlal Khamar, Rajiv Indravadan Modi, Indravadan Ambalal Modi, Prasanta Kumar Ghosh, Nirav Desai